Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombolysis for acute ischaemic stroke.

J M Wardlaw1, G Zoppo, T Yamaguchi

  • 1Clinical Neurosciences, The University of Edinburgh, Western General Hospital, Crewe Rd, Edinburgh, UK, EH4 2XU.

The Cochrane Database of Systematic Reviews
|August 15, 2003
PubMed
Summary

Thrombolytic therapy for acute ischemic stroke significantly reduces death or dependency, despite increasing early deaths and brain bleeds. Intravenous recombinant tissue plasminogen activator shows promise but requires further research for optimal use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Shaping the risk for late-life neurodegenerative disease: A systematic review on prenatal risk factors for Alzheimer's disease-related volumetric brain biomarkers.

Neuroscience and biobehavioral reviews·2023
Same author

Mediterranean-Type Diet and Brain Structural Change from 73 to 79 Years in the Lothian Birth Cohort 1936.

The journal of nutrition, health & aging·2022
Same author

European Stroke Organisation (ESO) standard operating procedure for the preparation and publishing of guidelines.

European stroke journal·2021
Same author

Cerebral small vessel disease burden and longitudinal cognitive decline from age 73 to 82: the Lothian Birth Cohort 1936.

Translational psychiatry·2021
Same author

Associations between total MRI-visible small vessel disease burden and domain-specific cognitive abilities in a community-dwelling older-age cohort.

Neurobiology of aging·2021
Same author

Uncertainties in short term prediction of atmospheric dispersion of radionuclides. A case study of a hypothetical accident in a nuclear floating power plant off the West coast of Norway.

Journal of environmental radioactivity·2021

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Ischemic stroke, often caused by brain artery blockages, requires prompt thrombolytic drug treatment to restore blood flow and improve recovery.
  • While effective, thrombolytic agents carry risks, including potentially fatal brain hemorrhages.

Purpose of the Study:

  • To assess the safety and efficacy of thrombolytic agents in patients experiencing acute ischemic stroke.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating thrombolytic agents versus control in acute ischemic stroke.
  • Searched multiple databases (Cochrane Stroke Group, MEDLINE, EMBASE) and contacted researchers for published and unpublished data.
  • Included 18 RCTs with 5727 patients, analyzing outcomes like death, dependency, and intracranial hemorrhage.

Related Experiment Videos

Main Results:

  • Thrombolytic therapy up to six hours post-stroke significantly reduced death or dependency (OR 0.84).
  • However, it increased early deaths (OR 1.81), primarily due to fatal intracranial hemorrhage (OR 4.34), and symptomatic intracranial hemorrhage (OR 3.37).
  • Treatment within three hours showed greater efficacy in reducing death/dependency (OR 0.66) with no significant increase in mortality.

Conclusions:

  • Thrombolytic therapy offers a net benefit in reducing death or dependency but increases early mortality and hemorrhage risks.
  • Intravenous recombinant tissue plasminogen activator (rt-PA) may offer less hazard and more benefit, but optimal patient selection, timing, and administration remain unclear.
  • While promising for selected patients in experienced centers, widespread routine use is not yet supported; further trials are needed to refine treatment protocols.